Mogroside V

Mogroside V is the primary bioactive triterpene glycoside extracted from monk fruit (Luo Han Guo), comprising up to 1% of the fruit's dry weight. It exerts antioxidant, anti-inflammatory, and potential anticancer effects primarily by scavenging reactive oxygen species and suppressing NF-κB and COX-2 signaling pathways.

Origin & History

Mogroside V is a triterpenoid glycoside extracted from the fruit pulp of Siraitia grosvenorii (luo han guo), a plant in the Cucurbitaceae family used in traditional Chinese medicine. It is isolated through water or solvent extraction of dried fruit followed by purification, yielding a white to off-white solid with molecular formula C₆₀H₁₀₂O₂₉.

Historical & Cultural Context

Mogroside V is derived from Siraitia grosvenorii fruit, which has been used for centuries in Traditional Chinese Medicine as a natural sweetener and for respiratory ailments including cough and sore throat. The compound provides the fruit's intense sweetness, up to 300 times that of sucrose.

Health Benefits

• May inhibit pancreatic cancer cell growth through apoptosis and angiogenesis inhibition (preclinical evidence only)
• Reduces inflammation by inhibiting COX-2 expression and NF-κB phosphorylation (in vitro studies)
• Supports cellular health through ROS scavenging and mitochondrial function (cell culture studies)
• Potential neuroprotective effects in Parkinson's disease models (animal studies only)
• Modulates glucose and lipid metabolism via AMPK pathway activation (preclinical evidence)

How It Works

Mogroside V suppresses inflammation by blocking IκB kinase phosphorylation, thereby preventing NF-κB nuclear translocation and downstream transcription of COX-2 and pro-inflammatory cytokines such as IL-6 and TNF-α. Its antioxidant activity stems from direct ROS scavenging and upregulation of endogenous antioxidant enzymes including superoxide dismutase (SOD) and catalase, partially mediated through Nrf2/HO-1 pathway activation. In pancreatic cancer models, mogroside V promotes apoptosis via caspase-3 and caspase-9 activation while inhibiting VEGF-driven angiogenesis, reducing tumor vascularization in preclinical assays.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Mogroside V were identified in the research dossier. All evidence comes from preclinical studies including in vitro experiments with PANC-1 pancreatic cancer cells and RAW264.7 macrophages, plus animal models for neuroprotection and metabolic effects.

Clinical Summary

The majority of evidence for mogroside V derives from in vitro cell line studies and rodent models, with no large-scale randomized controlled trials in humans published to date. In murine pancreatic cancer xenograft models, mogroside V administration reduced tumor volume by approximately 50% compared to controls, though translational relevance remains unestablished. Anti-inflammatory effects have been demonstrated in LPS-stimulated macrophage cultures and carrageenan-induced paw edema rat models at doses of 20–80 mg/kg, showing significant COX-2 and NF-κB suppression. Human clinical data are essentially absent for mogroside V in isolation, and extrapolating preclinical findings to therapeutic dosing in humans is premature.

Nutritional Profile

Mogroside V is a cucurbitane-type triterpenoid glycoside (C60H102O29, MW ~1287.4 g/mol) and the principal sweet compound in monk fruit (Siraitia grosvenorii), responsible for approximately 200-300× the sweetness of sucrose. It is a non-caloric, non-glycemic compound with no significant macronutrient contribution (zero protein, fat, carbohydrate metabolizable energy). Key bioactive properties stem from its five glucose moieties attached to the mogrol aglycone backbone, which confer potent antioxidant capacity (ORAC values significantly higher than vitamin C on a molar basis). Typical concentration in monk fruit extract standardized products ranges from 25-55% mogroside V by weight. Oral bioavailability is limited in intact form; gut microbiota hydrolyze mogroside V to mogrol and intermediate mogrosides (mogroside IIIE, mogroside IE) in the colon, and mogrol is the primary absorbed metabolite. Mogrol itself demonstrates significant anti-inflammatory and antioxidant bioactivity. No vitamins or minerals are present in the isolated compound.

Preparation & Dosage

No clinically studied dosage ranges have been established for Mogroside V as human trials are absent. The compound is commercially available as a purified solid for research use and as a non-caloric sweetener, but therapeutic dosing lacks clinical validation. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Mogroside V pairs well with **curcumin (200-500 mg as standardized 95% curcuminoids)** because both converge on NF-κB inhibition and COX-2 suppression, amplifying anti-inflammatory effects through complementary upstream targeting (curcumin inhibits IKKβ while mogroside V reduces NF-κB phosphorylation directly). **Epigallocatechin gallate (EGCG, 200-400 mg from green tea extract)** synergizes by enhancing ROS scavenging across different cellular compartments — EGCG primarily neutralizes superoxide and hydroxyl radicals in the cytosol while mogrol (the active metabolite) supports mitochondrial membrane integrity. **Piperine (5-10 mg from black pepper extract)** enhances the bioavailability of co-administered polyphenols and may improve intestinal absorption of mogrol metabolites by inhibiting hepatic and intestinal glucuronidation (UGT enzymes). **Sulforaphane (10-30 mg from broccoli seed extract)** complements mogroside V's antioxidant action by activating the Nrf2/ARE pathway, upregulating endogenous Phase II detoxification enzymes (glutathione S-transferase, NQO1), creating a dual exogenous-endogenous antioxidant defense strategy.

Safety & Interactions

Mogroside V and monk fruit extracts are generally recognized as safe (GRAS) by the FDA as food sweetening agents, with no significant adverse effects reported at typical dietary exposure levels. Because mogroside V may influence NF-κB and inflammatory signaling, theoretical interactions with immunosuppressant drugs such as corticosteroids or calcineurin inhibitors cannot be excluded, though no clinical interaction studies have been conducted. Pregnant and breastfeeding women should exercise caution due to the absence of controlled human safety data in these populations. Individuals with known hypersensitivity to Cucurbitaceae family plants, which includes monk fruit, should avoid supplementation.